A good companion
This article was originally published in Scrip
Executive Summary
GE Healthcare's announcement that it plans to invest up to $1 billion in oncology-focused life sciences research in the next five years could remove many of the shackles that have been hobbling the development of personalised or marker-defined medicine. The instrumentation giant is, in effect, positioning itself as a therapy-neutral technology broker and partner for pharmaceutical and biotechnology companies looking to develop biomarkers and companion diagnostics.